Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 92

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Central nervous system lymphoma

Not recruiting

Study on [18F]-Fludarabine and Gadoteric Acid for Imaging in Patients with Newly Diagnosed Primary CNS Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gadoteric Acid
  • Sponsor:Assistance Publique Hopitaux De Paris

Ischaemic stroke

Not recruiting

Study on Blood Pressure Management with Urapidil, Phenylephrine, and Labetalol for Patients with Acute Ischemic Stroke After Endovascular Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Urapidil
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Dementia Alzheimer's type

Not recruiting

Study on the Effects of ALZ-801 in Patients Aged 50-80 with Early Alzheimer's Disease and APOE4 Genotype

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Valiltramiprosate
  • Sponsor:Alzheon Inc.

Fragile X syndrome

Not recruiting

Study on the Effects and Safety of ZYN002 Gel for Children, Adolescents, and Young Adults with Fragile X Syndrome

Investigational
Countries:IrelandIreland
  • Participants:0–17 years · 18–64 years
  • Substances:Cannabidiol
  • Sponsor:Harmony Biosciences Management Inc.

Dystonic tremor

Not recruiting

Study on Botulinum Toxin Type A for Arm Tremor in Patients with Dystonia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Stichting Radboud University Medical Center

Circadian rhythm sleep disorder

Not recruiting

Study on the Effects of Tasimelteon for Patients with Delayed Sleep-Wake Phase Disorder

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tasimelteon
  • Sponsor:Vanda Pharmaceuticals Inc.

Neuroblastoma

Not recruiting

Study on Bevacizumab with Temozolomide and Irinotecan for Children with Relapsed or Refractory Neuroblastoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Spinal cord injury cervical

Not recruiting

Study on the Safety of NG004 for Patients with Acute Spinal Cord Injury

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ng004
  • Sponsor:NovaGo Therapeutics AG

Dementia Alzheimer's type

Not recruiting

A study of low-dose interleukin-2 (aldesleukin) treatment in patients with early Alzheimer's Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Primary progressive multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Melatonin and Ocrelizumab for Patients with Primary Progressive Multiple Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Benzyl Alcohol
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Friedreich's ataxia

Not recruiting

A Phase 2 Study to Evaluate Safety and Effectiveness of Omaveloxolone (RTA 408) in Patients with Friedreich's Ataxia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Omaveloxolone
  • Sponsor:Reata Pharmaceuticals Inc.

Neurofibromatosis

Not recruiting

Study on the Effect of Food on Selumetinib in Adolescents with Neurofibromatosis Type 1 Plexiform Neurofibromas

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Selumetinib
  • Sponsor:AstraZeneca AB

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.